NextGen is engaged in the development and commercial licensure of novel therapeutic proteins that disrupt the growth of cancers. NextGen`s drug and product portfolio includes a prostate cancer target and a brat cancer target as well as a promising acquisition pipeline.
Modern molecular biological tools have enabled cancer scientists to profile individual cells by their pattern of protein expression. Had it not been for such tools the cancer stem cell would have remained a needle in a haystack. However, it has now become possible not only to find the cancer stem cell but also to conduct a full fingerprinting profile which enables development of cell-specific cytotoxic treatments. Such treatment is superior to existing cancer therapies as it leaves healthy tissue intact whilst all malignant cells are eradicated.
